Momenta, Mylan to start trial of biosimilar to eye drug Eylea

This article was originally published here

Momenta Pharmaceuticals and Mylan have unveiled plans to commence pivotal clinical study of a biosimilar to Regeneron’s eye drug Eylea (aflibercept).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply